CBD Improved Memory and Reduced Anxiety in an Alzheimer's Mouse Model

In SAMP8 mice (a model for Alzheimer's disease), high-dose CBD (30 mg/kg daily for two months) significantly improved learning and memory in T-maze and novel object recognition tests. CBD-treated aged mice also showed less anxiety in the elevated plus maze. Biochemical analysis revealed decreased markers of oxidative stress in the brain.

Controlled animal study using SAMP8 mice (an accelerated aging model for Alzheimer's). Mice aged 11 months received vehicle or CBD (3 or 30 mg/kg) daily via oral gavage for 2 months. Young (3-month) vehicle-treated mice served as controls. Assessed learning/memory (T-maze, novel object recognition), anxiety (elevated plus maze), activity, and strength.

This adds to a small but growing body of preclinical evidence suggesting CBD may have neuroprotective properties relevant to age-related cognitive decline. The identification of reduced oxidative stress as a mechanism provides a plausible biological pathway.

Alzheimer's treatment options remain extremely limited. While animal studies cannot predict human outcomes, identifying compounds that improve cognitive function in validated disease models is an important early step in drug development.

Animal study only; results may not translate to humans. Small sample sizes typical of mouse studies. Only two doses tested. The SAMP8 model does not fully replicate human Alzheimer's pathology. No long-term follow-up after treatment ended.